JP2012067116A5 - - Google Patents

Download PDF

Info

Publication number
JP2012067116A5
JP2012067116A5 JP2011246211A JP2011246211A JP2012067116A5 JP 2012067116 A5 JP2012067116 A5 JP 2012067116A5 JP 2011246211 A JP2011246211 A JP 2011246211A JP 2011246211 A JP2011246211 A JP 2011246211A JP 2012067116 A5 JP2012067116 A5 JP 2012067116A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
composition according
initial dose
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011246211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012067116A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012067116A publication Critical patent/JP2012067116A/ja
Publication of JP2012067116A5 publication Critical patent/JP2012067116A5/ja
Withdrawn legal-status Critical Current

Links

JP2011246211A 2004-06-10 2011-11-10 ヒトの癌を処置するための、vegfインヒビターの使用 Withdrawn JP2012067116A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57849904P 2004-06-10 2004-06-10
US60/578,499 2004-06-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007527795A Division JP2008502738A (ja) 2004-06-10 2005-06-10 ヒトの癌を処置するための、vegfインヒビターの使用

Publications (2)

Publication Number Publication Date
JP2012067116A JP2012067116A (ja) 2012-04-05
JP2012067116A5 true JP2012067116A5 (https=) 2013-11-07

Family

ID=35510259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527795A Withdrawn JP2008502738A (ja) 2004-06-10 2005-06-10 ヒトの癌を処置するための、vegfインヒビターの使用
JP2011246211A Withdrawn JP2012067116A (ja) 2004-06-10 2011-11-10 ヒトの癌を処置するための、vegfインヒビターの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007527795A Withdrawn JP2008502738A (ja) 2004-06-10 2005-06-10 ヒトの癌を処置するための、vegfインヒビターの使用

Country Status (9)

Country Link
US (7) US7354580B2 (https=)
EP (2) EP1753442A2 (https=)
JP (2) JP2008502738A (https=)
CN (1) CN101102786A (https=)
AU (1) AU2005254058A1 (https=)
CA (1) CA2567686A1 (https=)
IL (1) IL179515A0 (https=)
MX (1) MXPA06014421A (https=)
WO (1) WO2005123104A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
ES2633574T3 (es) * 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
CA2615636A1 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
JP2009537606A (ja) * 2006-05-25 2009-10-29 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
HUE029445T2 (en) * 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗-vegf抗體
BRPI0918211A2 (pt) * 2008-12-23 2015-12-08 Genentech Inc métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
SG187012A1 (en) * 2010-07-19 2013-02-28 Hoffmann La Roche Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
MX368442B (es) * 2014-01-25 2019-10-02 Chengdu Kanghong Biotechnologies Co Ltd Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
CN104004058B (zh) * 2014-06-23 2016-06-08 栾晓鹏 有关白介素-33抑制剂多肽及其应用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
WO2016077227A2 (en) * 2014-11-14 2016-05-19 Genentech, Inc. Predicting response to a vegf antagonist
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR102652347B1 (ko) * 2016-01-25 2024-03-27 사노피 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법
US10947537B2 (en) * 2016-02-18 2021-03-16 University Of Massachusetts Method of treating VEGF/VEGFR resistant prostate cancer by combining the therapy with RAC1 inhibitors
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
EP3664803A4 (en) * 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
WO2019083172A1 (ko) * 2017-10-24 2019-05-02 국립암센터 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
WO2020106049A1 (ko) * 2018-11-20 2020-05-28 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성
KR20200094110A (ko) * 2019-01-29 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물
WO2020159171A2 (ko) * 2019-02-01 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US20220196166A1 (en) * 2020-12-18 2022-06-23 Nibco Inc. L-ball union drain valve
US11898643B1 (en) 2022-12-28 2024-02-13 Nibco Inc. Dual union ball drain valve with T-flow adjustability
US12140236B2 (en) 2023-02-08 2024-11-12 Nibco Inc. Dual union drain valve with reversible check inserts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
CA2519835A1 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression

Similar Documents

Publication Publication Date Title
JP2012067116A5 (https=)
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
US20200281921A1 (en) Cancer treatment with combination of plinabulin and taxane
US11576895B2 (en) Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2007515469A5 (https=)
JP2011511072A5 (https=)
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
CN105451750A (zh) 治疗人的实体肿瘤的诺氏梭菌
RU2015152860A (ru) Режим введения и составы для аденовирусов типа в
JP2008540364A5 (https=)
KR20130085939A (ko) 소세포 폐암의 치료 방법
TWI486172B (zh) 鼻咽癌治療的醫藥
JP2015514796A (ja) 2から30mg/kgの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
CN117442704A (zh) 一种治疗前列腺癌的药物组合及其应用
JP2013540725A5 (https=)
JP6549107B2 (ja) がんの処置のための、ro5503781、カペシタビン及びオキサリプラチンの組み合わせ
CN110494137A (zh) 哺乳类雷帕霉素靶蛋白抑制剂及氯喹于治疗癌症的用途
Papadopoulos et al. A phase Ia study in patients with advanced solid tumors for the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway
JP2025143272A (ja) がんを処置する方法及び使用
US10736873B2 (en) Medical uses of N-(2-aminoethyl)-N-(4-benzyloxy)-3-methoxybenzyl)thiophene-2-formamide hydrochloride
CN121370853A (zh) Psammaplysene D及其衍生物在制备抗慢性肝病的药物中的应用
WO2024222705A1 (zh) 用于治疗pd-l1表达阳性局部晚期或转移性nsclc患者的药物及其用途
CN114617969A (zh) 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用